Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immunoconjugate Therapy in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Latest Information Update: 30 Oct 2023
At a glance
- Drugs Polatuzumab vedotin (Primary) ; Autologous stem cell therapy; Filgrastim; Sargramostim
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
- Focus Adverse reactions
- 24 Oct 2023 Planned End Date changed from 15 Aug 2024 to 15 Aug 2025.
- 24 Oct 2023 Planned primary completion date changed from 15 Aug 2023 to 15 Aug 2024.
- 29 Oct 2021 Status changed from not yet recruiting to recruiting.